Frontlight ResearchEarly access
Taking peopleNo phase
Post-Market Registry for the Evaluation of RefluxStop in GERD Treatment
Key facts
- Who runs it
- Implantica CE Reflux Ltd.
- Where
- Germany, Italy, Norway, and Switzerland6 sites in 4 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 2,500 people, planned
- Started
- 20 Feb 2023
- Expected to end
- 31 Dec 2029
- Type of study
- Observational, 2 groups
- Treatments tested
- RefluxStop implantation
- Nissen fundoplication
- Record updated
- 1 April 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Willing and able to provide informed consent and to participate in the registry study,
- Patient's age ≥ 18 years or according to local legal age of adulthood if older,
- Documented GERD present for > 6 months,
- Patient has a 24-hour pH monitoring proven GERD with pH and/or impedance pH measurement, off PPI therapy for at least 7 days prior to testing. (Total distal esophageal pH must be <4 for >4.5% of time during a 24-hour monitoring and/or total reflux episodes of acid >55 or weakly acid >26 for >5 seconds at 5 cm above LES)
- Suitable to undergo general anesthesia and is a suitable laparoscopic surgery candidate as determined by the investigator
Who cannot take part
- History of bariatric surgery wherein the stomach fundus has been extirpated,
- Known sensitivity or allergies to silicone materials,
- Patients that are unable to comply with the registry study requirements, (for example due to major psychiatric disorder or are considered otherwise unsuitable for participation in the registry study according to the investigator's judgement)
- Presence of para-esophageal hernia or sliding hernia > 3 centimeters,
- Known presence of delayed gastric emptying, if no other cause for acid reflux could be diagnosed,
- Female patients who are pregnant or nursing,
- Intraoperative findings determined by the investigator that may result in unfavorable conduct of the registry study procedure (as outlined in the IFU)
This trial is currently available in Italy, Norway, and Switzerland.
It has sites in 4 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This post-market registry aims to assess safety and performance of RefluxStop™ in the treatment of Gastroesophageal Reflux Disease (GERD) in standard of care procedures.
The 2 groups in the trial
- RefluxStop patients
Treatment: RefluxStop implantation
- Nissen fundoplication patients
Treatment: Nissen fundoplication
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Post-market Registry Study to Assess Safety and Performance of RefluxStop™ in the Treatment of Gastroesophageal Reflux Disease (GERD) in General Hospital Practice
- Record updated
- 1 April 2025